274 related articles for article (PubMed ID: 36121667)
1. From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer.
Betge J; Jackstadt R
Int J Cancer; 2023 Apr; 152(7):1304-1313. PubMed ID: 36121667
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
Li J; Liu J; Xia W; Yang H; Sha W; Chen H
Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
Zhou Z; Cong L; Cong X
Front Oncol; 2021; 11():762184. PubMed ID: 35036354
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
[TBL] [Abstract][Full Text] [Related]
5. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
6. [Advances in three-dimensional tumor models for colorectal cancer].
Wang CT; Zhou JL; Lin GL; Yin SY; Cong L; Zhang GN; An Y; Qiu XY
Zhonghua Zhong Liu Za Zhi; 2023 Jun; 45(6):464-470. PubMed ID: 37355464
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
Ren X; Chen W; Yang Q; Li X; Xu L
J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
[TBL] [Abstract][Full Text] [Related]
8. The drug-induced phenotypic landscape of colorectal cancer organoids.
Betge J; Rindtorff N; Sauer J; Rauscher B; Dingert C; Gaitantzi H; Herweck F; Srour-Mhanna K; Miersch T; Valentini E; Boonekamp KE; Hauber V; Gutting T; Frank L; Belle S; Gaiser T; Buchholz I; Jesenofsky R; Härtel N; Zhan T; Fischer B; Breitkopf-Heinlein K; Burgermeister E; Ebert MP; Boutros M
Nat Commun; 2022 Jun; 13(1):3135. PubMed ID: 35668108
[TBL] [Abstract][Full Text] [Related]
9. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
Sasaki N; Clevers H
Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study.
Wang T; Pan W; Zheng H; Zheng H; Wang Z; Li JJ; Deng C; Yan J
Dis Colon Rectum; 2021 Jul; 64(7):833-850. PubMed ID: 33709991
[TBL] [Abstract][Full Text] [Related]
12. Modeling colorectal cancers using multidimensional organoids.
Sayed IM; El-Hafeez AAA; Maity PP; Das S; Ghosh P
Adv Cancer Res; 2021; 151():345-383. PubMed ID: 34148617
[TBL] [Abstract][Full Text] [Related]
13. Organoids as research models for hepatocellular carcinoma.
Yu JH; Ma S
Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
[TBL] [Abstract][Full Text] [Related]
15. Organoid in colorectal cancer: progress and challenges.
Ji DB; Wu AW
Chin Med J (Engl); 2020 Aug; 133(16):1971-1977. PubMed ID: 32826461
[TBL] [Abstract][Full Text] [Related]
16. Organoids: An intermediate modeling platform in precision oncology.
Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived organoids as a model for tumor research.
Wang J; Feng X; Li Z; Chen Y; Huang W
Prog Mol Biol Transl Sci; 2022; 189(1):259-326. PubMed ID: 35595351
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.
Pyo DH; Hong HK; Lee WY; Cho YB
Cancer Biol Ther; 2020 Jun; 21(6):495-502. PubMed ID: 32208894
[TBL] [Abstract][Full Text] [Related]
19. Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine.
Novelli G; Spitalieri P; Murdocca M; Centanini E; Sangiuolo F
Front Cell Dev Biol; 2022; 10():1059579. PubMed ID: 36699015
[TBL] [Abstract][Full Text] [Related]
20. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
[TBL] [
